💉
COVID-19 Vaccines
15 articles analyzed — Average score : 45/100
Grade distribution
Authors' conclusions
Articles
B
Mostly reliable (68/100)
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Positive
Sadoff J et al.·The New England Journal of Medicine·Jun 2021
B
Mostly reliable (66/100)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Positive
Polack FP et al.·New England Journal of Medicine·Dec 2020
B
Mostly reliable (65/100)
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. Positive
Voysey M et al.·Lancet·Jan 2021
B
Mostly reliable (63/100)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Positive
Logunov DY et al.·Lancet (London, England)·Feb 2021
C
Nuanced (53/100)
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Mixed
Lopez Bernal J et al.·The New England journal of medicine·Jul 2021
C
Nuanced (49/100)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Positive
Voysey M et al.·The Lancet·Jan 2021
C
Nuanced (49/100)
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Positive
Charmet T et al.·Lancet Regional Health – Europe·Jul 2021
C
Nuanced (47/100)
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. Mixed
Andrews N et al.·The New England journal of medicine·Apr 2022
D
Unreliable (44/100)
Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. Positive
Amanzio M et al.·Lancet Reg Health Eur·Jan 2022
D
Unreliable (41/100)
SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021. Positive
Fournier PE et al.·Frontiers in Microbiology·Jan 2022
D
Unreliable (39/100)
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. Positive
Greinacher A et al.·The New England Journal of Medicine·Apr 2021
D
Unreliable (29/100)
Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Negative
Klein NP et al.·JAMA·Oct 2021
D
Unreliable (28/100)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Positive
Khoury DS et al.·Nature medicine·May 2021
D
Unreliable (28/100)
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. Positive
Oster ME et al.·JAMA·Jan 2022
E
Not reliable (12/100)
The association between COVID-19 vaccination and Bell's palsy. Inconclusive
Cirillo N & Doan R·The Lancet. Infectious diseases·Aug 2021